quote.bloomberg.com
SCHEIN PHARMACEUTICAL TO MARKET NICOTINE TRANSDERMAL SYSTEM USP
FLORHAM PARK, N.J., Nov. 3 /PRNewswire/ -- Schein Pharmaceutical, Inc.
(NYSE: SHP) announced today that as a result of a licensing agreement with
Elan Corporation plc, it will be marketing Nicotine Transdermal System USP for
prescription use.
Nicotine Transdermal System USP product is the latest offering in our
successful relationship with Elan -- a relationship that has seen a number of
important products come to market over the past several months," said Martin
Sperber, Schein Pharmaceutical's chairman and chief executive officer.
The product, a generic version of Habitrol(R), is now available in the
United States in three dosage strengths: 7 mg/day, 14 mg/day and 21 mg/day.
Each carton contains 30 patches.
Schein Pharmaceutical, Inc. has a diverse portfolio of both brand and
generic products. Schein Pharmaceutical integrates its product development
expertise, diverse, high-volume production capacity and direct sales and
marketing force to capitalize on the commercialization of products. The
Company's brand products group has developed an expertise in the management of
anemia in nephrology, and is looking to expand this expertise to other
therapeutic areas. In addition, the Company develops, manufactures and
markets a broad generic product line including both solid and sterile dosage
products. The Company has a substantial pipeline of products under
development, and enhances its internal product development, manufacturing and
marketing capabilities through strategic collaborations. Schein
Pharmaceutical has manufacturing facilities in Arizona, Connecticut, New
Jersey, New York and Puerto Rico.
Habitrol(R) is a registered trademark of Novartis Pharmaceuticals
Corporation.
SOURCE Schein Pharmaceutical, Inc.
-0- 11/03/1999
/NOTE TO EDITORS: This release is available on the Internet at
schein-rx.com./
/CONTACT: Melody A. Carey, Investor Relations, 973-593-5535, fax,
973-593-5598, for Schein Pharmaceutical, Inc./
/Web site: schein-rx.com
(SHP)
CO: Schein Pharmaceutical, Inc.; Elan Corporation plc; Novartis
Pharmaceuticals Corporation
ST: New Jersey
IN: MTC BIO TOB
SU: PDT LIC
-0- Nov/03/1999 7:00
EOS (PRN) Nov/03/1999 07:00 85
-0- (PRN) Nov/03/1999 7:15
ia
-
NYSE/AMEX delayed 20 min. NASDAQ delayed 15 min. |
